A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma.

被引：2
|
作者：
Konner, Jason A.
Boucicaut, Nicole N.
O'Cearbhaill, Roisin Eilish
Zamarin, Dmitriy
Makker, Vicky
Sabbatini, Paul
Tew, William P.
Cadoo, Karen Anne
Grisham, Rachel N.
Aghajanian, Carol
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5572
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Cadoo, Karen A.
    Grisham, Rachel N.
    O'Cearbhaill, Roisin E.
    Boucicaut, Nicole N.
    Henson, Melissa
    Iasonos, Alexia
    Zhou, Qin
    Sarasohn, Debra M.
    Gallagher, Jacqueline
    Kravetz, Sara
    Zamarin, Dmitriy
    Makker, Vicky
    Sabbatini, Paul J.
    Tew, William P.
    Aghajanian, Carol
    Konner, Jason A.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (01) : 214 - 221
  • [2] Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers
    McMeekin, D. D.
    Lanneau, G.
    Curiel, J.
    Moore, K.
    Walker, J.
    Mannel, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer
    Konner, J. A.
    Grabon, D.
    Pezzulli, S.
    Iasonos, A.
    Sabbatini, P.
    Hensley, M.
    Bell-McGuinn, K.
    Tew, W.
    Spriggs, D.
    Aghajanian, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma
    Nagao, S.
    Oishi, R.
    Iwasa, N.
    Shimizu, M.
    Hasegawa, K.
    Goto, T.
    Fujiwara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study
    McMeekin, D. Scott
    Sill, Michael W.
    Walker, Joan L.
    Moore, Kathleen N.
    Waggoner, Steven E.
    Thaker, Premal H.
    Rizack, Tina
    Hoffman, James S.
    Fracasso, Paula M.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (01) : 36 - 40
  • [6] A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group Study
    McMeekin, D. Scott
    Sill, Michael W.
    Walker, Joan L.
    Moore, Kathleen N.
    Waggoner, Steven E.
    Thaker, Premal H.
    Rizack, Tina
    Hoffman, James S.
    Fracasso, Paula M.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2015, 70 (10) : 626 - 628
  • [7] A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Bell-McGuinn, Katherine M. y
    Brady, William E.
    Schilder, Russell J.
    Fracasso, Paula M.
    Moore, Kathleen N.
    Walker, Joan L.
    Duska, Linda R.
    Mathews, Cara Amanda
    Chen, Alice
    Shepherd, Stacie Peacock
    Giranda, Vincent L.
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer
    Konner, J. A.
    Fallon, K.
    Pezzuli, S.
    Iasonos, A.
    Sabbatini, P.
    Hensley, M.
    Chiang, A.
    Tew, W.
    Spriggs, D.
    Aghajanian, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: A feasibility study.
    Nagao, S.
    Nishikawa, T.
    Kurosaki, A.
    Ohishi, R.
    Iwasa, N.
    Hasegawa, K.
    Fujiwara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial.
    Wenzel, LB
    Huang, H
    Armstrong, D
    Walker, J
    Cella, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 455S - 455S
12345